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Abstract. We present the preliminary results of a study of two novel thiosemicarbazones (TSCs) and their ruthenium complexes.
The TSCs were prepared by refluxing thiosemicarbazide with 9-anthraldehyde or benzanthrone in ethanol for 3 hours. The metal
= [(r|6 H)Ru(9-ant-TSC )(C1)]C1
complex ofeach ligand (complex I
-C6 6
and complex II= [(r|6-C6H6)Ru(benz-TSC)(Cl)]Cl) was prepared
by refluxing the appropriate TSC with [(r|6-C6H6)RuCl 2]r The compounds were characterized using infrared, ultraviolet-visible, and
NMR spectroscopy. Two different methods, the disk diffusion test and luminometry, were used to test the compounds against a variety
of different bacterial strains for antibacterial activity. The most optimistic results were obtained for the 9-ant-TSC ligand, especially
in relation to activity against Gram (+) bacteria. The metal complexes showed no measurable activity and further biological testing of
the metal complexes is currently being conducted.
Key words:

— thiosemicarbazones

(TSCs), ruthenium complexes, bacterial strains.

free uncomplexed TSCs show interesting biological activity,
in a number of cases the transition metal complexes showed
greater biological activity (Pandeya and Dimmock 1993,
Quiroga and Ranninger 2004). This can be related to increased
lipophilicity which controls entry into the cell. It has also been
proposed that the mechanism of antibacterial activity involves
electron transfer and/or oxidative stress (Kovacic et al. 1989).
Other positive effects ofmetal coordination include potentially
significant reduction of drug resistance and side effects (West et
al 1991). It is conceivable that coordination to the metal serves
to activate the biologically active TSC ligand. Also, the metal
complex can exhibit different bioactivities than the free TSCs.
By coupling the TSCs with the organometallic Ru(II) group, it
may be possible to synthesize new complexes that have good
biological activity due to the synergistic effectiveness.
In this paper we report the synthesis of organometallic
ruthenium complexes with novel thiosemicarbazone ligands
(Fig. 2) and describe their characterization and antimicrobial

Introduction
In modern chemotherapy the aim is to use a chemical
compound that kills the offending organism or cells while
having minimal impact ofother cells. While most of the current
chemotherapeutic agents are organic compounds, the use of
inorganic (defined as metal-based) compounds has been growing
in importance over the last 30 years. Indeed one of the most
important anticancer drugs is c«-diamminedichloroplatinum
(II),cisplatin, whichis especially useful for the treatment ofsolid
malignancies. Cisplatin however exhibits serious renal toxicity
and has a narrow-spectrum of activity (being applicable to only
a few tumor types). This has led to a continuing effort to design
transition metal-based drugs that improve on spectrum activity
and are also less toxic when compared to cisplatin. In other
biomedical spheres, metal-based compounds are also gaining
prominence. For example, the activity of organic antimicrobials
such as chloroquine (a drug used to treat malaria) has been
enhanced by binding the organic molecule to a ruthenium center.
The Ru(II)-chloroquine complex is 2-5 fold more effective than
chloroquine alone (Dyson and Allardyce 2001).
Organometallic compounds exhibit different ligand kinetics
in solution to coordination complexes, which could prove
advantageous in the design of inorganic drugs. Metallocenes
of the type M0f-C5 H5 )2X2 (M Ti, V,Nb, and Hf) have shown
moderate anticancer behavior (Clarke et al. 1999). Ru(II) arene
complexes of the type [(r|6-arene)Ru(X Y)(Z)]+ are cytotoxic to
cancer cells including cisplatin-resistant cell lines (Morris et al.
2001, Airdetal. 2002).
Thiosemicarbazones (TSCs, Fig. 1) have received
considerable attention because they present a wide range of
bioactivities: antibacterial, antifungal, anti-neoplastic, and
antiviral (Beraldo and Gambino 2004). They thus represent an
important class of compounds that have aroused considerable
interest in chemistry and pharmacology. The properties of
TSCs are usually affected by metal coordination. Although the

activity.

-

Fig. 1: Thiosemicarbazones

showing thione (I)

thiol (II)

tautomerism
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was reacted with an equimolar amount of thiosemicarbazide in
refluxing ethanol for 3 hours. The orange precipitate (yellow for
benzanthrone) that formed was filtered, washed with copious
amounts of ethanol, then ether, and dried at the vacuum pump.
The yield was 82.7% for 9-ant-TSC
— and 43.4% for benz-TSC.
Preparation of complexes. The complexes were prepared
as follows: [(Tf-C6H6)RuCl2]2 (300 mg, 0.600 mmol)and the TSC
(1.20 mmol) were dissolved in 40 mL of degassed toluene and
the solution was stirred during reflux in an inert atmosphere for
4 hours. The brown precipitate (black for benzanthrone) was
filtered, washed with copious amounts of pentane, and dried at
the vacuum pump. The yield was 73.5% for I
— and 53.5% for II.
Antibacterial activity screens. The ligands were
screened against standard bacterial strains of Staphylococcus
aureus, Escherichia
coli, Bacillus cereus, Enterococcus
faecalis, Salmonella typhimurium, and Proteus vulgaris. The
antibacterial activity was studied by luminometry for the first 2
bacterial strains and by the disk diffusion method for the latter
4. For the luminescence assay, the bacteria were incubated
in Mueller-Hinton broth at 37 °C for 20 hours. The cultures
were diluted 1:100 in fresh M-H broth, and then 245 \a\ of the
appropriate culture was added to 12 wells of a 24-well plate.
Five microliters of the appropriate drug, 9-ant-TSC, benz-TSC,
or chloramphenicol (the standard), all at 10' 5 M were added to
4 wells of each culture, and the cultures were grown at 37 °C

for an additional 5 hours. Luminescence was then measured
as counts per second (CPS). For the disk diffusion test, small
7-mm-diameter circles of filter paper (P5) were saturated with
20 ul of the test solutions (10 3 M in DMSO). The disks were
placed on agar plates that were inoculated with the bacterial
cultures, and the plates were incubated at 37 °C for 20 hours.
Chloramphenicol was used as a standard. Following incubation,
each plate was checked for zones ofinhibition (measured inmm).
Antibacterial activity screens for I
and IIusing disk diffusion
were also conducted, but the results were inconclusive.

benzTSC

9-ant-TSC

Fig. 2: Structures ofthe thiosemicarbazones

and complexes

Materials and Methods
Analyticalor reagent grade chemicals were used throughout.
Hydrated RuCl3 was purchased from Strem (Newburyport,
MA) and used as received. Allother chemicals were obtained
from Sigma-Aldrich (St. Louis, MO) or other commercial

Results and Discussion

vendors and used as received. The luminometry studies were
done using a BacTiter-Glo™ Microbial Cell Viability Assay
(Promega, Madison, WI) on a Hidek Bioscan single-tube
combination liquid scintillation counter and luminometer.
Microanalyses (C, H, N) were performed by Desert Analytics
(Tucson, AZ). 'H and 13C NMR spectra were recorded on a
Bruker spectrometer operating at 300 MHz in chloroform-^
or dichloromethane-i/ 2 The chemical shifts were measured in
ppm relative to TMS. IR spectra were recorded in KBr discs
- 450 era 1 on a Mattson Satellite FTIR
in the range 4000
spectrophotometer, and the electronic spectra were recorded
on an Agilent 8453 spectrophotometer in the range 190-1100
nm using quartz cuvettes. Melting points were determined in
open capillaries and are uncorrected. The precursor complex
[(r|6-benzene)RuCl 2], was prepared following the method of
Bennett and Smith (1974).

—

Syntheses. Figure 2 shows the ligands and complexes
prepared in this study. The ligands were made by condensing
the aldehyde (9-anthraldehyde) or ketone (benzanthrone) with
thiosemicarbazide as shown in Scheme 1 for 9-ant-TSC. The
starting ruthenium dimer [(r|6-benzene)RuCl ]2 was made
2
following the method of Bennett and Smith (1974) by heating
at reflux a methanolic solution of RuCl3 .xH2O with 1,3- or
1,4-cyclohexadiene.
From this precursor compound, target
complexes (Fig. 2) were synthesized according to Scheme 2.
Generally, the ruthenium dimer is reacted with two equivalents
of the ligand in toluene at elevated temperatures. The complexes
precipitated directly from the reaction solution on cooling to
ambient temperature.
—
MeltingPoints. Shown inTable 1are the meltingpoints for
the TSCs and their complexes. The TSCs melted over a narrow

.

Preparation

of TSC.

—9-anthraldehyde

(or benzanthrone)
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Scheme 2. Synthesis of the metal complexes
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the complex), which is likely a result of a weakening of the C=S
bond. This indicates that the thione group is probably involved

9-ant-TSC

inmetal coordination.
Vibrational Spectra.

Scheme 1. Synthesis of the thiosemicarbazones

—The

infrared spectral data for the
ligands and complexes are shown in Table 2. Despite the fact
that the HN-C=S group can undergo thione-thiol tautomerization
(Fig. 1), the lack of a band around 2570 cm 1 (characteristic of
S-H bonds) indicates that the TSCs are in the thione form in the
solid state. The presence of bands around 3150 cm" 1 indicates
the presence of the -NH moiety, which further supports the
thione coordination. These bands shift somewhat from the TSC
to the related metal complex, possibly indicating involvement
of the azomethinic nitrogen in complex formation. However,
the N-N stretching (which occurs around 1015 cm 1) does not
vary much between TSC and the metal complex (2-7 cm- 1),
which leads to the conclusion that the azomethinic nitrogen is
not involved in formation of the complexes. Instead, the C=N
band experiences a greater degree ofshift between the TSC and
metal complex (~14 cm 1). Thus, itis concluded that the imine
nitrogen is involved in metal coordination. The C=S bands for
the TSCs is also shifted upon complex formation (from 827 to
809 cm 1 for 9-ant-TSC and from 1279 to 1297 cm 1 for benzTSC), further indicating thione involvement in binding to the
metal. The NH2 bands show some amount of shift (as high as
24 cm 1), but this occurred as a consequence ofthe coordination
ofthe -S=C-NH 2 to the metal.
—
Antimicrobial Studies. In vitro antibacterial properties
of the TSCs are shown in Tables 3 and 4. Both TSCs showed
littleor no effect on Gram (-) bacteria, as determined from both
the luminometry and disk-diffusion tests. In fact, no activity
was seen for either TSC against the two Gram (-)bacteria in the
disk-diffusion test, and both were about 4 times less effective
against E. coli than against S. aureus in the luminometry assay.
Benz-TSC also showed little effect against Gram (+) bacteria
in the disk-diffusion test (0.5 mm), but had slightly higher
effectiveness against S. aureus in comparison with 9-ant-TSC.
Optimistic results for the 9-ant-TSC, especially in relation to
Gram (+) bacteria, were obtained from the disk-diffusion test.
Against E. faecalis, 9-ant-TSC was even more active than the
chloramphenicol standard (bacteriostatic diameter of 10 mm,
in comparison with4 mm for the standard). Further studies are
being done on this compound in an effort to establish minimum
inhibitory concentration (MIC) values. Further biological

range (1.7-2. 8°C), indicating relative purity of these compounds
(as a melting range ofabout 2°C is generally considered normal
for pure compounds). Neither complex showed any melting
behavior below 350°C.
—
NMR Spectra. The NMR data for the two ligands
are consistent with the proposed structures. The 1H NMR
spectrum of 9-ant-TSC in CD2C12 shows two singlets at 9.00
ppm and 9.74 ppm that are assigned to the HC=N' and HN2
protons respectively. The azomethinic (HN2) proton might be
expected to show up at higher frequencies (11-14 ppm) but is
shifted upfield in our spectrum. This is not unusual however
as in a number of thiosemicarbazones the signal ascribed to
this group show up in the range 8-11 ppm. The thione form
of the ligand exists in solution as well as there is no peak at ~
4.00 ppm in the 'H NMR which corresponds to -SH. It has
been reported that this resonance typically appears at ~ 4.0 ppm
(Singh et al 2005). The aromatic resonances for both ligands
appear at the expected positions (7.5-8.5 ppm). The 13C NMR
spectra show a high frequency signal at 180.4 ppm for 9-antTSC and 184.1 ppm for benz-TSC. These are assigned to the
-C=S moiety. The -C=N signal occurs at 141.4 ppm for 9-antTSC and 136.4 ppm for benz-TSC. Inboth compounds there is
a cluster of peaks in the 120-130 ppm range, which is typical
for aromatic compounds.

Electronic Spectra. —UV-Vis electronic spectra of both
TSCs and complexes I
and IIwere analyzed using 10"5 M
DMSO solutions in the 190-900 nm region. Data from the
analysis is presented in Table 1. The bands occurring at <300
nm can most likely be attributed to n-n* transitions, while
the bands between 350-400 nm are most likely due to n-7t*
transitions of the thiosemicarbazone ligands. While the major
absorbance wavelengths for the TSCs didn't change much (010 nm) on formation of their respective complexes, there were
hypochromic changes at each peak (0.02-0.73). This clearly
indicates electron density movement between the ligand and the
metal. The n-n* transitions also show small changes inmolar
absorptivity (a general decrease ofabout 0.05 from the TSC to
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Table 1. Solution Electronic Spectral Data (nm) for Selected Thiosemicarbazones
DMSO solutions)
Compounds
9-ant-TSC a (208.0

Wavelength (molar absorptivity)

- 210.8°C) b

231 (4.53) c

264 (4.68)

373 (3.76)

392 (3.84)

I(>350°C)

231(4.49)

263(4.56)

375(3.72)

393(3.82)

benz-TSC (154.1 155.8°C)

231(4.49)

266(4.15)

276(4.15)

393(4.05)

231(4.54)
log (e)

262(4.10)

398(3.31)

405(3.32)

-

II(>350°C)
a

and their Ruthenium Arene Complexes (10 5 M

5

=1 x 10-

Min DMSO; b

Melting Points;

c

-

Table 2. Selected Vibrational Bands (cm 1) ofThiosemicarbazones and Complexes I
and II
Assignment

9-ant-TSC

1

benz-TSC

v (C=N)

1600

1614

1620

1622

v (N-N)

1019

1017

1001

1286
827
3157
3440
3263

1285
809 (w)
3146
3417
3287

1279
842

1008 (w)
1297 (w)
843

3179
3385
3264

3168
3386
3283

\) (C=S)

O)(NH)

m (NH )
2

II

w = weak

and Complexes I
and II(10~3 M) Bacteriostatic Diameter (mm)
Bacterial strain
Gram (+)
1
Gram (-)

Table 3. Antibacterial Activity ofthe Thiosemicarbazones

...
faecahs

_,

„

10

benz-TSC

0.5

0.5

0

0

II
Chloramphenicol

9,5

4

4J>

8J5

9-ant-TSC

|

.

,

3

cereus

Enterococcus

.

Proteus
vulgans
0

Bacillus

Salmonella typnimunum
0

I

....

a=

Results inconclusive

and II(10 3 M) Luminescence (CPS)
Table 4. Antibacterial Activity of the Thiosemicarbazones and Complexes I
Bacterial strain
Gram (-)
Compound
Gram (+)
Staphylococcus aureus
|
Escherichia coli
1.30 x 10 7
5.72 x 10 7
9-ant-TSC
I

Benz-TSC
ii
Chloramphenicol
Negative Control (Background)

1.18xlO 7

5.72 x 10 7

3.22 x 10 6
1.13 x 10 5

3.39 x 10 6
1.13 x 10 s

a=

Results inconclusive
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nitrothiophene-2-carboxaldehyde

testing of the metal complexes is being conducted, but the
preliminary results have been inconclusive.

—The authors

and physical correlations in the biological properties
of transition metal heterocyclic thiosemicarbazone and
S-alkyldithiocarbazate complexes. Struct and Bonding
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